Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action

BMC Psychiatry
Xingqin ZhouZhiwen Yao

Abstract

Clozapine has remarkable efficacy on both negative and cognitive symptoms of schizophrenia due to its slight activation of NMDA receptor. In fact, much evidence to the contrary. NMDAR is a complex containing specific binding sites, which are regulated to improve negative symptoms and cognitive deficits associated with individuals affected by schizophrenia. PQQ is a powerful neuroprotectant that specifically binds with NMDA receptors in the brain to produce beneficial physiological and cognitive outcomes. The aim of this study was to enhance NMDAR function and improve cognitive ability in schizophrenia by PQQ combined with clozapine. Rats were divided into four groups (n = 5) including control (saline), model (MK-801, 0.5 mg·kg- 1·d- 1), atypical antipsychotic (MK-801 (0.5 mg·kg- 1·d- 1) + Clozapine (1.0 mg·kg- 1·d- 1), and co-agonist NMDA receptor (MK-801 (0.5 mg·kg- 1·d- 1) + Clozapine (0.5 mg·kg- 1·d- 1) + PQQ (1.0 μg·kg- 1·d- 1) group. Each group of rats was injected subcutaneously every day for 6 weeks. Behavior test, including stereotyped behavior, locomotor hyperactivity, learning and memory, was performed. The Western blot assay was performed to analyze the expression of GSK-3β, Akt, NMDAR1, and MGLUR in rat hippocampus....Continue Reading

References

Mar 29, 2000·The Journal of Nutrition·T E StitesR B Rucker
Sep 26, 2001·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·R G Morris
Jan 5, 2002·Antioxidants & Redox Signaling·C Anthony
Sep 5, 2003·Psychopharmacology·Philip D HarveyJohn H Krystal
Jan 28, 2004·Nature Genetics·Effat S EmamianJoseph A Gogos
Mar 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jean-Martin BeaulieuMarc G Caron
Jun 19, 2004·Psychopharmacology·J David Sweatt
Aug 4, 2004·Psychopharmacology·Jinhua WuLei Yu
Nov 4, 2004·Biological Psychiatry·Masashi IkedaNorio Ozaki
Jan 12, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Anissa Abi-Dargham, Marc Laruelle
May 12, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Tobias EngelJosé J Lucas
Feb 28, 2007·Trends in Neurosciences·Simon LovestoneRobin Murray
Sep 21, 2007·Current Psychiatry Reports·Mitsuru Toda, Anissa Abi-Dargham
Sep 13, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Stefano PorcelliAlessandro Serretti
Dec 17, 2011·Current Medicinal Chemistry·C BonaccorsoM Zappalà
Sep 19, 2012·Schizophrenia Bulletin·Joseph T Coyle
Feb 26, 2014·Physiological Research·V VyklickyL Vyklicky
Mar 24, 2015·European Archives of Psychiatry and Clinical Neuroscience·Silvana GalderisiArmida Mucci
Aug 25, 2015·Schizophrenia Research·Alfredo SpagnaJin Fan
Apr 26, 2016·Behavioural Brain Research·Xingqin ZhouShishi Mao
Jun 23, 2018·Current Pharmaceutical Biotechnology·Moritz HaafChristoph Mulert

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here